Insider buying last 90 days
No open-market insider purchases were filed for ZLAB in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ZLAB insider filing, plotted on the chart in Gekko.Open ZLAB in Gekko
Gekko Brief
AI summaryOct 12 closeZai Lab draws attention this week around its upcoming presentation of global Phase 1b/1c data for its lung cancer drug zocilurtatug pelitecan at the 2026 ESMO Congress, a DLL3-targeting antibody drug conjugate that is reshaping the company's investment narrative. This sits alongside continued discussion of Q2 2026 results, which showed an 11% sequential increase in net product revenue to $105.8 million and maintained commercial profitability, as the company frames its transition from a China-focused commercial business to a global biopharmaceutical firm. Separately, coverage has compared Zai Lab with peer Cytokinetics (CYTK) on profitability, valuation and ownership.
Zai Lab closed at $24.59, down 1.6% on the day, sitting between its 50-day average of $25.00 and 200-day average of $20.63, with the stock up 27.4% over three months but down 24.8% over the past year. The GekkoIndex reads 60.1, placing the stock in the Accumulation zone. Price sits 12.7% below Gekko Fair Value of $28.18.
The next earnings report is due 5 November 2026 before the open, 24 days away and within a typical 20-trading-day holding window; the prior quarter saw a 26.9% reaction following an EPS beat. No insider, Congress or unusual options activity appears in the recent windows. Seasonally, the next 20 trading days have averaged a 0.7% return over five years, rising in three of them. The ESMO data presentation and the approaching earnings date are both worth noting over this stretch.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Zai Lab price vs fair value
Close $24.59200-day averageGekko Fair Value $28.18
Zai Lab quick facts
- Market cap
- $2.78B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.70
- Revenue, TTM
- $449.6M
- Profit margin
- -41.9%
- Dividend yield
- —
- Beta
- 0.72
- Volume
- 524,502 avg 803,093
- 1-year return
- −24.8%
- Typical daily move
- ±4.6%
- Typical 20-day move
- ±12.8%
- 50-day average
- $25.00
- 200-day average
- $20.63
- Next earnings
- Nov 5 before open
- Shares outstanding
- 112.3M
Zai Lab swing-trade checklist
Zai Lab scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $24.59 sits between the 50-day ($25.00) and 200-day ($20.63) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
60.1, Accumulation
Reading 60.1 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
12.7% below
Price is 12.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.7% on average
From this point in the calendar, the next 20 trading days averaged +0.7% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Zai Lab stock chart and price history
Zai Lab closed at $24.59 on Oct 12, 2026, −24.8% over the past year, inside a 52-week range of $15.96 to $32.76.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.9%
- 3 months
- +27.4%
- 6 months
- +15.2%
- 1 year
- −24.8%
The full ZLAB chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ZLAB in Gekko
Follow Zai Lab through every session
Put ZLAB on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ZLAB in GekkoFree for 7 days. No credit card required.
About Zai Lab
Zai Lab works in biopharmaceuticals, with activities concentrated in Mainland China and Hong Kong. The company researches, develops and brings to market medical treatments across oncology, autoimmune disease, infectious disease and neurological conditions. It currently markets several products, among them Zejula, a PARP inhibitor taken once daily; Optune, a device using tumor treating fields; NUZYRA, used against certain bacterial skin infections and pneumonia; and Qinlock, used for gastrointestinal stromal tumors.
Alongside these marketed therapies, Zai Lab runs a wide pipeline of experimental treatments addressing cancers, infections and neurological or psychiatric disorders, including candidates aimed at lymphomas, lung and gastric cancers, EGFR-driven tumors, and serious bacterial infections, among others still in development.
Zai Lab was founded in 2013 and is headquartered in Shanghai, China. Its shares trade under the ticker ZLAB.
- Sector
- Health technology
- Website
- zailaboratory.com
Zai Lab GekkoIndex: the smart money zone
Zai Lab’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.1, in the Accumulation zone, up 3 points over five sessions.
60.1Accumulation
Up 3 points over five sessions, from the Neutral zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 4 | Too few readings yet | |||
| Accumulation (current zone) | 41 | +4.6% | +14.4% | ||
| Neutral | 77 | +0.3% | +2.6% | ||
| Distribution | 14 | −1.1% | −5.1% | ||
| Selling | 3 | Too few readings yet | |||
Average ZLAB share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ZLAB price, zone by zone.Track ZLAB in Gekko
Is Zai Lab stock overvalued? Gekko Fair Value
Zai Lab trades 12.7% below Gekko Fair Value of $28.18, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Zai Lab shares are worth, recalculated every trading day.
$28.18
Gekko Fair Value, Oct 10, 2026
12.7% Undervalued
At the end of Aug 2026 the price was 12.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ZLAB in Gekko
Zai Lab insider and Congress trading
No open-market insider purchases were filed for Zai Lab, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ZLAB were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ZLAB, plotted on the chart in Gekko.Open ZLAB in Gekko
Buybacks
Zai Lab has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $2.20M
- As a share of market cap
- 0.08%
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold ZLAB.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Zai Lab earnings: next date and track record
Zai Lab reports on Nov 5, 2026, before the open (24 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 24 days away
- EPS estimate
- −$0.56
- Revenue estimate
- $108.8M
3 of 8reports beat the EPS estimate
±8.6%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Zai Lab's Q2 2026 call emphasized a strategic transition from a China-focused commercial company to a global biopharmaceutical company driven by an advancing R&D pipeline and disciplined commercial execution. Management highlighted momentum across core commercial products (11% sequential net product revenue growth to $105.8M), commercial profitability, and continued demand for key brands (ZEJULA, VYVGART, XACDURO, KarXT). The pipeline narrative centered on Zoci (DLL3 ADC) progressing rapidly from IND to global registrational trials with plans for Phase III enrollment completion in H1 2027, a potential U.S. accelerated approval submission in late 2027 and approval anticipated in 2028; combination studies with PD-L1 and T cell engagers are planned and ESMO data (approx. 60 patients) will be presented in October. ZL-1503 (long-acting IL-13/IL-31 bispecific) will report first human data later this year and MAD data next year; MUC17 T-cell engager IND is targeted by year-end. Financially, management reiterated disciplined investment, expects stabilization of product sales in H2 2026, and a return to meaningful year-over-year growth in 2027 driven by new launches and potential NRDL inclusion, with a potential first U.S. product launch in 2028. The tone combined confident technical progress and commercialization optimism with measured caution on near-term revenue volatility due to NRDL timing, supply constraints, and competitive/regulatory uncertainty.
- Guidance
- Expect 3 registrational programs in small cell lung cancer and neuroendocrine carcinoma by year-end 2026; present Zoci combination data at ESMO in October 2026 (approx. 60 patients); global Phase III enrollment for Zoci expected to complete in H1 2027; U.S. accelerated approval submission for Zoci anticipated later in 2027 and approval anticipated in 2028; report first human data for ZL-1503 later in 2026 and MAD data in 2027; target IND for MUC17 TCE by year-end 2026; management expects stabilization of product sales in H2 2026 and a return to meaningful year-on-year growth in 2027. (No specific numeric revenue or EPS guidance was provided.)
- Risks flagged
- Near-term revenue may be affected by NRDL-related timing and the transition of VYVGART from IV to subcutaneous; supply constraints for XACDURO; competitive pressure in atopic dermatitis (IL-13/IL-31 class); clinical and regulatory risk for novel programs (ADC/TCE toxicities such as CRS and ILD, need for favorable safety for combo regimens); reliance on partner timelines (e.g., Amgen for combination data) and potential manufacturing scale-up risks.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.46 est −$0.66 | $106.3M est $103.9M | +26.9% |
| May 7, 2026 | −$0.46 est −$0.29 | $99.61M est $108.4M | −11.5% |
| Feb 26, 2026 | −$0.46 est −$0.44 | $127.6M est $122.2M | −0.9% |
| Nov 6, 2025 | −$0.33 est −$0.28 | $116.1M est $126.7M | −11.7% |
| Aug 7, 2025 | −$0.37 est −$0.37 | $110.0M est $150.2M | −9.7% |
| May 8, 2025 | −$0.45 est −$0.50 | $106.5M est $112.6M | +3.1% |
| Feb 27, 2025 | −$0.80 est −$0.61 | $109.1M est $109.3M | −1.2% |
| Nov 12, 2024 | −$0.42 est −$0.75 | $102.3M est $108.9M | −3.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Zai Lab stock forecast and analyst price targets
Analysts’ average 12-month price target for Zai Lab is $33.14, +34.8% from the last close, from 1 firm rating the stock in the last 90 days.
$33.14consensus 12-month target, +34.8% from the last close
Each firm’s latest rating in the last 90 days: 1 firm.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 1 | J.P. Morgan | $36 | +46.4% |
| Aug 27 | J.P. Morgan | $36 | +46.4% |
+14.4%average 20-day move after past Accumulation readings
+0.7%average move over the next 20 trading days in the last 5 years
±4.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Zai Lab seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Zai Lab averaged +0.7% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.6% | 2 of 5 |
| Next 10 trading days | −2.8% | 3 of 5 |
| Next 15 trading days | −1.6% | 3 of 5 |
| Next 20 trading days | +0.7% | 3 of 5 |
| Next 30 trading days | −5.4% | 3 of 5 |
For scale, ZLAB’s typical 20-trading-day move in either direction is about 12.8%.
Zai Lab market cap and key statistics
Zai Lab’s market cap is $2.78B and revenue of $449.6M over the last twelve months.
Valuation
- Market cap
- $2.78B
- EPS, TTM
- −$1.70
- Gekko Fair Value
- $28.18
Trading
- Volume
- 524,502
- Avg volume, 20 days
- 803,093
- 52-week high
- $32.76
- 52-week low
- $15.96
- Shares outstanding
- 112.3M
Financials
- Revenue, TTM
- $449.6M
- Profit margin
- -41.9%
- Return on equity
- -26.9%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.72
- Typical daily move
- ±4.6%
- Typical 20-day move
- ±12.8%
Zai Lab stock news this week
Coverage of Zai Lab this week reads neutral: 2 positive, 3 neutral and 0 negative headlines.
- Current ratio of Zai Lab Ltd. – HAM:1ZLBTradingView, Oct 12
- Zai Lab (ZLAB) Sets Up ESMO Data Debut, Is The Stock Still Cheap?Simply Wall Street, Oct 11
- Did Trial Data Debut Just Shift Zai Lab (ZLAB) Stock Narrative?Simply Wall Street, Oct 8
- Analyzing Zai Lab (NASDAQ:ZLAB) and Cytokinetics (NASDAQ:CYTK)Defense World, Oct 8
- Form 4 Zai Lab Ltd For: Oct 01 Filed by: Chen YajingStreetInsider, Oct 5
- Zai Lab Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga, Oct 5
Zai Lab stock FAQ
What is Zai Lab’s market cap?
Zai Lab’s market cap is $2.78B at the Oct 12, 2026 close of $24.59, with 112.3M shares outstanding.
What is the Zai Lab stock forecast?
The consensus analyst 12-month price target for Zai Lab is $33.14, +34.8% from the last close. Of the 1 firm that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Zai Lab stock overvalued or undervalued?
On Gekko’s estimate Zai Lab is undervalued: the Oct 12, 2026 close of $24.59 is 12.7% below Gekko Fair Value of $28.18. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Zai Lab report earnings next?
Zai Lab is expected to report on Nov 5, 2026, before the market opens (24 days away). Analysts expect earnings of −$0.56 per share on revenue of $108.8M. Zai Lab beat the earnings estimate in 3 of its last 8 reports, moving 8.6% on average across the report.
What is Zai Lab’s 52-week high and low?
Zai Lab’s 52-week high is $32.76 and its 52-week low is $15.96; it closed at $24.59 on Oct 12, 2026, −24.8% over the past year. Over the last five years the shares peaked at $105.85 on Oct 27, 2021.
Is Zai Lab stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Zai Lab the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.